Healthcare [ 11/13 ] | Diagnostics & Research [ 95/159 ]
NASDAQ | Common Stock
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally.
It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.
The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services.
The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security.
The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002.
Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 8, 24 | -0.09 Increased by +70% | -0.31 Increased by +70.97% |
| Dec 7, 23 | -0.26 Decreased by -2.5 K% | -0.27 Increased by +3.7% |
| Aug 10, 23 | -0.24 Decreased by -84.62% | -0.24 |
| May 11, 23 | 0.05 Increased by +121.74% | -0.2 Increased by +125% |
| Feb 9, 23 | -0.3 Increased by +52.38% | -0.29 Decreased by -3.45% |
| Dec 14, 22 | -0.01 Increased by +98.33% | -0.26 Increased by +96.15% |
| Aug 11, 22 | -0.13 Increased by +71.74% | -0.35 Increased by +62.86% |
| May 12, 22 | -0.23 Increased by +30.3% | -0.33 Increased by +30.3% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 891.16 K Decreased by -83.07% | -1.18 M Increased by +69.22% | Decreased by -132.73% Decreased by -81.75% |
| Sep 30, 23 | 779.74 K Decreased by -78.09% | -3.59 M Decreased by -364.68% | Decreased by -460.7% Decreased by -2.02 K% |
| Jun 30, 23 | 2.92 M Decreased by -32.1% | -3.1 M Decreased by -175.73% | Decreased by -106.25% Decreased by -306.06% |
| Mar 31, 23 | 4.41 M Decreased by -28.3% | 588.34 K Increased by +152.18% | Increased by +13.35% Increased by +172.78% |
| Dec 31, 22 | 5.26 M Increased by +26.34% | -3.84 M Increased by +18.6% | Decreased by -73.03% Increased by +35.57% |
| Sep 30, 22 | 3.56 M Increased by +17.09% | -773.07 K Increased by +82.86% | Decreased by -21.72% Increased by +85.36% |
| Jun 30, 22 | 4.3 M Increased by +152.68% | -1.12 M Increased by +67.4% | Decreased by -26.17% Increased by +87.1% |
| Mar 31, 22 | 6.15 M Increased by +130.1% | -1.13 M Increased by +25.67% | Decreased by -18.34% Increased by +67.7% |